Product Description
Edgewise Therapeutics is developing EDG-003, it is currently in the research stage to treat metabolic disorders. (Sourced from: https://www.sec.gov/Archives/edgar/data/1710072/000115752321001387/a52527144ex99_1.htm)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Edgewise Therapeutics
Company Location: Western America
Company CEO: Kevin Koch
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Metabolic Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|